DEF: Zenas BioPharma Sets Date for 2025 Annual Stockholders Meeting, Director Elections and Auditor Ratification on the Agenda

Zenas BioPharma announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring director elections and ratification of the company's auditor.

Summary

• Zenas BioPharma will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, at 8:00 a.m. Eastern Time.
• Stockholders will vote to elect two Class I director nominees, Leon O. Moulder, Jr. and Hongbo Lu, Ph.D., to serve until the 2028 Annual Meeting.
• The meeting will also include a vote to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2025.
• The board of directors has set April 14, 2025, as the Record Date for determining stockholders eligible to vote.
• The board recommends voting 'FOR' the election of each director nominee and 'FOR' the ratification of the accounting firm appointment.
• Stockholders can participate in the virtual meeting at www.virtualshareholdermeeting.com/ZBIO2025 using the control number on their proxy card or notice.
• As of the Record Date, 41,834,182 shares of common stock were issued and outstanding.
• Ting (Tim) Xiao will not stand for reelection as a director at the expiration of his term on June 10, 2025.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining the agenda and procedures for the upcoming annual meeting. While there are no explicit negative statements, the presence of forward-looking statements and inherent business risks temper the overall sentiment.

Positives

• The virtual meeting format aims to provide a consistent experience for all stockholders, regardless of location.
• The company believes the virtual format expands stockholder access, improves communications, and lowers costs while reducing environmental impact.
• The board of directors is actively engaged in overseeing the management of the company's risks through its committees.
• The company has adopted a Corporate Governance Guidelines and a Code of Business Conduct and Ethics to ensure ethical and responsible business practices.
• The company has adopted an Incentive Compensation Clawback Policy to recoup erroneously awarded incentive-based compensation.
• The company has adopted an insider trading policy and an anti-hedging policy to promote compliance with securities laws and protect stockholder interests.

Negatives

• The company's CEO also serves as the Chairman of the board, which may raise concerns about potential conflicts of interest.
• The company's Nominating and Corporate Governance Committee did not meet during the year ended December 31, 2024, which may raise concerns about the effectiveness of its oversight.
• The company's Audit Committee fees increased significantly from $677,776 in 2023 to $1,725,000 in 2024, which may warrant further scrutiny.

Risks

• The Proxy Statement contains forward-looking statements that are subject to risks and uncertainties, and actual results may differ materially from those projected.
• The company operates in an evolving environment, and new risks and uncertainties may emerge from time to time.
• The company's success depends on its ability to attract, retain, and motivate qualified personnel.
• The company's business is subject to various legal and regulatory risks, including those related to accounting matters, financial reporting, and cybersecurity.
• The company's compensation policies and practices may create risks if not properly designed and implemented.

Future Outlook

The Proxy Statement contains forward-looking statements about the company's board of directors, corporate governance practices, executive compensation program, and equity compensation utilization, which are subject to risks and uncertainties.

Management Comments

• Leon O. Moulder, Jr., Chief Executive Officer and Chairman, encourages stockholders to vote as promptly as possible.
• The company has adopted a virtual meeting format for the Annual Meeting to provide a consistent experience to all stockholders regardless of geographic location.

Industry Context

The use of a virtual meeting format is becoming increasingly common among public companies to enhance stockholder access and reduce costs.

Comparison to Industry Standards

• The company's director compensation policy is generally in line with industry standards for similarly sized companies.
• The company's executive compensation program is designed to align executive compensation with the company's business objectives and to attract, retain, and reward executive officers who contribute to the company's long-term success.
• The company's corporate governance practices are generally consistent with industry best practices.

Management Changes

Related Party Transactions

• In May 2024, the company issued Series C Preferred Stock to several related parties, including entities affiliated with SR One Capital Management, Delos Capital Fund III, Enavate Sciences, Longitude Capital, and Fairmount Funds Management LLC.
• The company has entered into agreements with Dianthus Therapeutics Inc. and Viridian Therapeutics Inc., which may be considered related party transactions due to overlapping ownership and board representation.

Stakeholder Impact

• Stockholders are encouraged to participate in the Annual Meeting and vote on the proposals.
• The election of directors and ratification of the auditor will impact the company's governance and financial oversight.
• The company's executive compensation program is designed to align the interests of executives with those of stockholders.
• The company's related party transactions are subject to review and approval by the Audit Committee to ensure fairness and transparency.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 10, 2025.
• The company will announce the voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Corporate Governance, Executive Compensation, Zenas BioPharma, Stockholders